Audrey Greenberg

Venture Partner | CEO | Founder | Board Member | Investor

Greater Philadelphia

About

๐— ๐—ฎ๐˜†๐—ผ ๐—ฉ๐—ฒ๐—ป๐˜๐˜‚๐—ฟ๐—ฒ ๐—ฃ๐—ฎ๐—ฟ๐˜๐—ป๐—ฒ๐—ฟ | ๐—•๐—ถ๐—ผ๐˜๐—ฒ๐—ฐ๐—ต ๐—•๐˜‚๐—ถ๐—น๐—ฑ๐—ฒ๐—ฟ | ๐—–๐—ฎ๐—ฝ๐—ถ๐˜๐—ฎ๐—น ๐—ฆ๐˜๐—ฟ๐—ฎ๐˜๐—ฒ๐—ด๐—ถ๐˜€๐˜ I turn moonshot ideas into market-shaping companies and build the teams, capital, and strategy required to scale them. Recognized globally as an award-winning executive with a proven track record of scaling businesses at the intersection of science, capital, and impact. I specialize in launching and scaling high-growth startups through capital formation, strategic partnerships, differentiated positioning, and world-class team development. My portfolio includes several multi-billion-dollar companies, and my experience spans C-suite leadership across strategy, finance, operations, and commercialization. I currently serve as a Mayo Venture Partner leading enterprise-wide efforts in venture creation, strategic capital formation, institutional spinouts, and the commercialization of transformative science and care delivery models. I work across the Mayo ecosystem to build and scale the next generation of healthcare companies, from therapeutics and diagnostics to enabling platforms and digital health. I serve on multiple boards and am active in industry organizations focused on womenโ€™s leadership, healthcare innovation, and public-private collaboration. Previously, I founded the Center for Breakthrough Medicines, one of the largest cell and gene therapy contract development and manufacturing organizations in the world. I raised over $500 million to build the company and led its rapid scaling before its acquisition by SK Group and integration into SK pharmtecoโ€™s CDMO platform. Prior to CBM, I spent two decades as a private equity executive, investment banker, and CPA, with deep expertise in M&A, corporate finance, and investing. I hold an MBA from the Wharton School and am a registered CPA in Illinois. I have been recognized with honors including Endpoints Top Women in Biopharma, Medicine Maker Power List (2x), Titan 100 (3x), Titan Hall of Fame, Philly Power 100, Most Influential Philadelphian, Women of Influence, Leader of the Year, and Healthcare Power Player. Under my leadership, my companies received accolades including Startup of the Year, DEI Initiative of the Year, Tech Translator of the Year, Deal of the Year (2x), and Employer of the Year. My North Star: ๐™—๐™ช๐™ž๐™ก๐™™๐™ž๐™ฃ๐™œ ๐™ซ๐™š๐™ฃ๐™ฉ๐™ช๐™ง๐™š๐™จ ๐™ฉ๐™๐™–๐™ฉ ๐™ฉ๐™ง๐™–๐™ฃ๐™จ๐™›๐™ค๐™ง๐™ข ๐™˜๐™–๐™ง๐™š, ๐™š๐™ก๐™š๐™ซ๐™–๐™ฉ๐™š ๐™š๐™ญ๐™ฅ๐™š๐™ง๐™ž๐™š๐™ฃ๐™˜๐™š, ๐™–๐™ฃ๐™™ ๐™จ๐™˜๐™–๐™ก๐™š ๐™ฌ๐™๐™–๐™ฉ ๐™ข๐™–๐™ฉ๐™ฉ๐™š๐™ง๐™จ.

Experience

  • Mayo Venture Partner and Chair Business Development at Mayo Clinic
    May 2025 - Present ยท 1 yr 2 mos

    As a Mayo Venture Partner, I focus on translating breakthrough science and clinical insight into scalable companies and strategic partnerships. My work sits at the intersection of venture creation, capital strategy, and healthcare innovation. I work across Mayo Clinicโ€™s research and clinical ecosystem to identify high-potential technologies, build companies around them, and connect them with the capital, partners, and leadership needed to scale globally. Core responsibilities include: โ€ข Leading venture spinouts, joint ventures, and co-creation opportunities with industry โ€ข Structuring equity-based partnerships across biopharma, medtech, diagnostics, and digital health โ€ข Building a venture creation engine connected to Mayoโ€™s clinical and research strengths โ€ข Enhancing portfolio value through strategic development, positioning, and capital strategy โ€ข Collaborating with scientists, clinicians, operators, and investors to translate discoveries into real-world impact

  • Board Member at Various Companies
    Jan 2021 - Present ยท 5 yrs 6 mos

    Serve as a board director and strategic advisor to venture-backed companies, industry organizations, and public company boards, including: โ€ข Adamas Trust ($ADAM) โ€ข Mill Creek Life Sciences โ€ข ZSX Medical โ€ข University of Penn, Penn Medicine, Abramson Cancer Center Innovation Advisory Board โ€ข Ben Franklin Technology Partners โ€ข Alliance for Regenerative Medicine

  • Chief Business Officer, Center for Breakthrough Medicines at SK pharmteco
    2019 - 2024 ยท 5 yrs

  • Founder and Chief Business Officer at Center for Breakthrough Medicines
    2019 - 2024 ยท 5 yrs

  • Senior Vice President, Exeter Europe (now EQT) at EQT Group
    2017 - 2019 ยท 2 yrs